158 related articles for article (PubMed ID: 29169164)
1. A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).
Ghazzawi M; Mehra V; Knut M; Brown L; Tapper W; Chase A; de Lavallade H; Cross NCP
Acta Haematol; 2017; 138(4):198-200. PubMed ID: 29169164
[No Abstract] [Full Text] [Related]
2. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
[No Abstract] [Full Text] [Related]
3. RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib.
Such E; Liquori A; Mora E; Marco-Ayala J; Avetisyan G; Regadera A; Ibañez F; Panadero J; Senent L; Llop M; Díaz A; Vicente A; Luna I; Ibáñez M; Barragán E; Sanz MA; Sanz G; Communidad Valenciana ; Cervera J
Acta Haematol; 2019; 142(2):92-97. PubMed ID: 31085913
[TBL] [Abstract][Full Text] [Related]
4. A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
Zhang Y; Qu S; Wang Q; Li J; Xu Z; Qin T; Huang G; Xiao Z
Leuk Lymphoma; 2018 Oct; 59(10):2506-2508. PubMed ID: 29384404
[No Abstract] [Full Text] [Related]
5. Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome.
Saultz JN; Kaffenberger BH; Taylor M; Heerema NA; Klisovic R
JAMA Dermatol; 2016 Dec; 152(12):1391-1393. PubMed ID: 27681117
[No Abstract] [Full Text] [Related]
6. Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.
Yoshida M; Tamagawa N; Nakao T; Kanashima H; Ueda H; Murakami A; Yorifuji T; Yamane T
Leuk Lymphoma; 2015 Mar; 56(3):768-9. PubMed ID: 24975316
[No Abstract] [Full Text] [Related]
7. A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).
Iriyama N; Takahashi H; Naruse H; Miura K; Uchino Y; Nakagawa M; Iizuka K; Hamada T; Hatta Y; Nakayama T; Takei M
Mol Genet Genomic Med; 2019 Apr; 7(4):e00591. PubMed ID: 30697976
[TBL] [Abstract][Full Text] [Related]
8. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene.
García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM
Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041
[No Abstract] [Full Text] [Related]
9. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.
Li Z; Yang R; Zhao J; Yuan R; Lu Q; Li Q; Tse W
Pediatr Blood Cancer; 2011 Mar; 56(3):463-6. PubMed ID: 21072821
[TBL] [Abstract][Full Text] [Related]
10. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.
Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR
Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate for unmutated hypereosinophilic syndromes: Does it work?
Helbig G
Eur J Intern Med; 2016 Jul; 32():e19-20. PubMed ID: 26968968
[No Abstract] [Full Text] [Related]
12. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
[TBL] [Abstract][Full Text] [Related]
13. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
[TBL] [Abstract][Full Text] [Related]
14. Eosinophilia in Hematologic Disorders.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
[TBL] [Abstract][Full Text] [Related]
15. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
16. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.
Shimomura Y; Maruoka H; Ishikawa T
Int J Hematol; 2017 May; 105(5):697-701. PubMed ID: 28000100
[TBL] [Abstract][Full Text] [Related]
17. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
18. The hypereosinophilic syndrome: idiopathic or not, that is the question.
Cools J
Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372
[No Abstract] [Full Text] [Related]
19. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
Cross NC; Reiter A
Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
[TBL] [Abstract][Full Text] [Related]
20. The results of imatinib therapy for patients with primary eosinophilic disorders.
Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
[No Abstract] [Full Text] [Related]
[Next] [New Search]
